Brief: Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation For Zygel In 22Q11.2 Deletion Syndrome
15/11/2022 12:42
Nov 15 (Reuters) - Zynerba Pharmaceuticals Inc ZYNE.O :
* ZYNERBA PHARMACEUTICALS ANNOUNCES EUROPEAN COMMISSION HAS
GRANTED ORPHAN DRUG DESIGNATION FOR ZYGEL™ IN 22Q11.2 DELETION
SYNDROME
Source text for Eikon: ID:nGNXbY6KXp
Further company coverage: ZYNE.O
Recent news on Zynerba Pharmaceuticals
See all newsBrief: Harmony Biosciences Completes Acquisition Of Zynerba Pharmaceuticals
Brief: Harmony Biosciences Announces Extension Of Tender Offer To Acquire Zynerba Pharmaceuticals, Inc.
Brief: Zynerba Pharmaceuticals Presents Positive Data From Phase 2 Inspire Trial
U.S. RESEARCH ROUNDUP-Easterly Government Properties, Visa, Zynerba Pharmaceuticals
Zynerba Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary